Jack Wallace
Stock Analyst at Guggenheim
(2.32)
# 2,507
Out of 4,854 analysts
19
Total ratings
52.63%
Success rate
8.5%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $285.36 | -12.74% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $56.33 | -69.82% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $4.10 | +241.46% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $152.32 | +44.43% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $26.81 | +49.20% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $6.96 | +1,336.78% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $22.94 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $285.36
Upside: -12.74%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $56.33
Upside: -69.82%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $4.10
Upside: +241.46%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $152.32
Upside: +44.43%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $26.81
Upside: +49.20%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $6.96
Upside: +1,336.78%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $22.94
Upside: -